New York Life Investment Management LLC Sells 2,880 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

New York Life Investment Management LLC lessened its position in SI-BONE, Inc. (NASDAQ:SIBNFree Report) by 13.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,072 shares of the company’s stock after selling 2,880 shares during the period. New York Life Investment Management LLC’s holdings in SI-BONE were worth $384,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. grew its position in shares of SI-BONE by 37.9% in the 1st quarter. JPMorgan Chase & Co. now owns 167,745 shares of the company’s stock valued at $3,791,000 after buying an additional 46,086 shares during the last quarter. HighTower Advisors LLC bought a new stake in shares of SI-BONE in the 1st quarter valued at about $220,000. MetLife Investment Management LLC grew its position in shares of SI-BONE by 54.2% in the 1st quarter. MetLife Investment Management LLC now owns 18,825 shares of the company’s stock valued at $425,000 after buying an additional 6,615 shares during the last quarter. Rhumbline Advisers grew its position in shares of SI-BONE by 8.3% in the 1st quarter. Rhumbline Advisers now owns 32,233 shares of the company’s stock valued at $728,000 after buying an additional 2,476 shares during the last quarter. Finally, BlackRock Inc. grew its position in shares of SI-BONE by 0.4% in the 1st quarter. BlackRock Inc. now owns 2,709,443 shares of the company’s stock valued at $61,233,000 after buying an additional 9,645 shares during the last quarter.

Insider Transactions at SI-BONE

In related news, CFO Anshul Maheshwari sold 1,733 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $17.59, for a total value of $30,483.47. Following the transaction, the chief financial officer now directly owns 148,738 shares of the company’s stock, valued at approximately $2,616,301.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Anshul Maheshwari sold 1,733 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $17.59, for a total value of $30,483.47. Following the completion of the transaction, the chief financial officer now owns 148,738 shares of the company’s stock, valued at approximately $2,616,301.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Anthony J. Recupero sold 1,936 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $20.93, for a total transaction of $40,520.48. Following the transaction, the insider now directly owns 198,903 shares of the company’s stock, valued at approximately $4,163,039.79. The disclosure for this sale can be found here. Insiders have sold a total of 28,465 shares of company stock valued at $546,469 in the last ninety days. 5.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on SIBN. Cantor Fitzgerald reduced their price target on SI-BONE from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 7th. Needham & Company LLC restated a “buy” rating and set a $25.00 target price on shares of SI-BONE in a research report on Monday, December 4th. Truist Financial upped their target price on SI-BONE from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 22nd. Finally, Morgan Stanley cut their price target on SI-BONE from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, November 7th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $26.33.

Get Our Latest Stock Analysis on SI-BONE

SI-BONE Stock Down 0.4 %

Shares of NASDAQ:SIBN opened at $21.02 on Monday. The stock’s 50-day moving average is $19.95 and its 200 day moving average is $20.03. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.89 and a quick ratio of 9.74. The company has a market cap of $851.31 million, a PE ratio of -17.66 and a beta of 1.27. SI-BONE, Inc. has a 1 year low of $15.10 and a 1 year high of $29.51.

SI-BONE Profile

(Free Report)

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma.

Further Reading

Want to see what other hedge funds are holding SIBN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SI-BONE, Inc. (NASDAQ:SIBNFree Report).

Institutional Ownership by Quarter for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.